Novartis to Make Pluvicto Radioligand Therapy at Indianapolis Plant
2024年1月6日 - 12:15AM
Dow Jones News
By Mauro Orru
Novartis received approval from the Food and Drug Administration
to produce its Pluvicto radioligand therapy at its new
manufacturing facility in Indianapolis, expanding capacity to meet
growing demand for cancer patients in North America.
The Swiss pharmaceutical company said Friday that the decision
from the FDA would lift radioligand therapy production capacity to
250,000 doses in 2024 and beyond. Novartis also has facilities in
New Jersey, Italy and Spain.
"Adding a second US RLT facility, our largest and most advanced
yet, into our manufacturing network underscores our commitment to
ensure a consistent and reliable experience for patients and their
healthcare teams for years to come," said Steffen Lang, president
of operations. "We also recently announced plans to build our
manufacturing capabilities in Sasayama, Japan and Haiyan, Zhejiang,
China, as we continue to look for opportunities to further expand
our worldwide reach."
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
January 05, 2024 10:00 ET (15:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
過去 株価チャート
から 4 2024 まで 5 2024
Novartis (NYSE:NVS)
過去 株価チャート
から 5 2023 まで 5 2024